Topic: Prostate cancer.
Destination: Pfizer will fund training initiatives aimed at enhancing the understanding of the need for conducting HRM (homologous recombination repair gene mutation) testing for metastatic prostate cancer in clinical practice.
Budget: 500.000$.
Duration: Less than 1 year.
Fill out the form below to receive more information:
